KM Financial Solutions | UPDATE 1-Forward Pharma loses appeal in Tecfidera patent dispute with Biogen
33360
post-template-default,single,single-post,postid-33360,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

UPDATE 1-Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

UPDATE 1-Forward Pharma loses appeal in Tecfidera patent dispute with Biogen

A U.S. federal appeals court on Wednesday
upheld a ruling that Biogen Inc’s patents on its blockbuster
multiple sclerosis drug Tecfidera are valid, rejecting a
challenge by Danish drugmaker Forward Pharma A/S.

No Comments

Sorry, the comment form is closed at this time.